✦ LIBER ✦

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 : 39810: A Phase II trial of cancer and leukemia group B

✍ Scribed by Gerald Clamon; James Herndon; Jeffrey Kern; Ramaswamy Govindan; Jennifer Garst; Dorothy Watson; Mark Green

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 100 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20950

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 4′-deoxydoxorubicin (D

Phase II trial of 4′-deoxydoxorubicin (DxDx) in non-small cell lung cancer: A cancer and leukemia group B trial

✍ Ringenberg, Q. Scott ;Perry, Michael C. ;Propert, Kathleen J. ;Modeas, Caron ;Hi 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study

✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 1 views

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin

Phase II trial of irinotecan, paclitaxel

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 3 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

Final survival and safety results from a

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

✍ David R. Spigel; Ming Lin; Vincent O'Neill; John D. Hainsworth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, mult

Gemcitabine and vinorelbine in the secon

Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients : A Minnie Pearl Cancer Research Network Phase II trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Joan B. Erland; Jerem 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## BACKGROUND. Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficacy of two active new agents, gemcitabine and v